GleamWall
中文EN

AGIO AGIOS PHARMACEUTICALS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1439222 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY214.4%
TTM net income YoY7.1%
TTM EPS YoY10.0%
Revenue 3-yr CAGR80.3%
Net income 3-yr CAGR—

Margins

Gross margin93.8%
Operating margin-297.7%
Net margin-264.8%
FCF margin-238.5%
EBITDA margin—

Returns

ROE-32.9%
ROA-30.4%
ROIC (approx.)-32.4%
Asset turnover0.11x

Leverage & solvency

Liabilities / assets8.0%
Debt / equity0.00x
Current ratio9.69x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.89x
Accruals ratio-3.4%
Payout ratio—
Capex / revenue3.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$55.38M$44.74M$20.75M$19.97M$12.88M$12.46M$8.73M$10.73M
Cost of revenue$2.52M$3.00M$1.32M$1.88M$1.68M$1.70M$1.08M$1.26M
Gross profit$52.86M$41.75M$19.43M$18.09M$11.20M$10.75M$7.64M$9.47M
R&D expense$73.49M$100.75M$81.15M$88.06M$86.80M$91.94M$72.74M$82.81M
SG&A expense$56.53M$51.55M$48.30M$51.61M$41.27M$45.87M$41.53M$51.70M
Operating income-$77.16M-$110.55M-$110.03M-$121.58M-$116.87M-$127.06M-$106.63M-$125.04M
Pretax income———-$109.06M-$103.43M——-$105.40M
Income tax———-$1.02M$0——-$8.88M
Net income-$65.05M-$100.70M-$99.11M-$108.04M-$103.43M-$112.02M-$89.29M-$96.52M
EPS (basic)-1.09-1.69-1.69—-1.78-1.93-1.55—
EPS (diluted)-1.09-1.69-1.69—-1.78-1.93-1.55—
Weighted avg. shares (diluted)59.71M59.49M58.78M—58.14M57.93M57.46M—
Balance sheet
Cash & equivalents$128.55M$99.65M$113.60M$89.13M$92.71M$80.87M$78.96M$76.25M
Short-term investments$501.46M$517.93M$623.44M$765.29M$860.15M$858.07M$814.41M$817.46M
Inventory$37.84M$35.75M$35.09M$32.92M$32.03M$30.85M$29.61M$27.62M
Current assets$752.10M$717.67M$834.84M$942.05M$1.03B$1.02B$968.62M$965.60M
PP&E, net$10.36M$9.95M$10.57M$10.78M$10.68M$10.58M$11.07M$11.68M
Total assets$1.06B$1.11B$1.18B$1.30B$1.39B$1.47B$1.56B$1.66B
Current liabilities$77.59M$70.22M$58.84M$82.21M$74.76M$70.41M$52.37M$81.16M
Total liabilities$84.70M$82.40M$75.88M$104.11M$101.38M$101.68M$88.99M$122.24M
Shareholders' equity$979.34M$1.03B$1.11B$1.19B$1.28B$1.37B$1.47B$1.54B
Shares outstanding59.78M59.60M59.34M58.45M58.28M58.04M57.89M57.16M
Cash flow statement
Operating cash flow-$59.24M-$57.31M-$118.92M-$96.21M-$88.15M-$77.12M-$111.49M-$133.17M
Capital expenditure$1.18M$1.21M$769,000$1.12M$1.55M$875,000$766,000$967,000
Free cash flow-$60.42M-$58.52M-$119.69M-$97.33M-$89.71M-$78.00M-$112.25M-$134.13M
Investing cash flow$83.96M$40.21M$141.31M$90.08M$95.56M$78.97M$112.59M-$49.16M
Financing cash flow$4.18M$3.15M$2.08M$2.56M$4.43M$65,000$1.62M$4.84M
Stock-based compensation$16.67M$15.94M$15.54M$14.12M$12.38M$14.69M$11.36M$10.90M

Free plan shows the latest 8 periods; Pro shows all 59 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.